Mazdutide Information

Mazdutide (also known as IBI362 or LY3305677) is an investigational drug, currently in clinical trials, primarily for the treatment of obesity and type 2 diabetes.

It is a novel type of therapeutic agent known as a dual agonist.

 

How Mazdutide Works?

Mazdutide is a novel therapeutic agent classified as a dual agonist. It is a synthetic peptide engineered to mimic the action of the naturally occurring gut hormone oxyntomodulin.

Its unique effectiveness stems from its ability to simultaneously activate two key receptors in the body:

1. Glucagon-Like Peptide-1 (GLP-1) Receptor Activation

This component provides effects similar to other established drugs for diabetes and weight loss:

• Improved Blood Sugar Control: It stimulates the pancreas to release insulin in a glucose-dependent manner (only when blood sugar is high), and suppresses the release of glucagon (a hormone that raises blood sugar).
• Appetite Suppression (Satiety): It acts on the brain to increase the feeling of fullness and reduce appetite, leading to lower food intake and reduced body weight.
• Delayed Gastric Emptying: It slows down how quickly food leaves the stomach, further promoting satiety and managing post-meal glucose spikes.

2. Glucagon Receptor (GCGR) Activation

This is the key differentiating component, contributing to enhanced metabolic and weight loss benefits:

• Increased Energy Expenditure: Activation of the GCGR, primarily in the liver, promotes the mobilization and breakdown of stored fat (lipolysis), effectively increasing the rate at which the body burns calories.
• Improved Lipid Metabolism: This action has been shown to help reduce liver fat content, lower overall blood lipids (triglycerides and cholesterol), and reduce visceral fat accumulation.

In summary, the dual action of Mazdutide provides a "one-two punch" against metabolic dysfunction: the GLP-1 component primarily improves blood sugar and suppresses appetite, while the Glucagon component promotes increased energy use.